Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, and MuseCell Innovations® Pte. Ltd. (“MCI”), the owner of the Dezawa MuseCell platform, today announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells (“DMCs”) at Celularity’s Florham Park, New Jersey facility.
MuseCell Innovations Enters U.S. Market, Bringing Restorative Stem Cell Therapy Directly to American PatientsMuseCell Innovations (MCI), the exclusive global licensor of Dezawa MuseCells®, today announced its U.S. launch. By making this restorative therapy available domestically, MCI eliminates the need for overseas patient travel, democratizing access to authentic Dezawa MuseCell® therapy through licensed providers in Florida, Utah, Tennessee and Georgia, with additional states to likely follow.
